Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity

Human Heredity

Volumn 75, Issue 1, 2013, Pages 34-43

  Gorden, Alexis ^a   Yang, Rongze ^a   Yerges Armstrong, Laura M ^a   Ryan, Kathleen A ^a   Speliotes, Elizabeth ^b   Borecki, Ingrid B ^c   Harris, Tamara B ^d   Chu, Xin ^e   Craig Wood, G ^e   Still, Christopher D ^e   Shuldiner, Alan R ^a,f   Gerhard, Glenn S ^e,g  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e GEISINGER MEDICAL CENTER   (United States)

^f BALTIMORE VA MEDICAL CENTER   (United States)

^g PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Cirrhosis; Dyslipidemia; Obesity; Steatohepatitis; Steatosis

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BARIATRIC SURGERY; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS; HUMAN; HUMAN TISSUE; LIPID BLOOD LEVEL; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; NCAN GENE; NONALCOHOLIC FATTY LIVER; PHENOTYPE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STEATOSIS; TRIACYLGLYCEROL BLOOD LEVEL; FATTY LIVER; INFLAMMATION; MIDDLE AGED;

ADULT; CHOLESTEROL; CHONDROITIN SULFATE PROTEOGLYCANS; FATTY LIVER; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; LECTINS, C-TYPE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; OBESITY, MORBID; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIGLYCERIDES;

EID: 84876083866     PISSN: 00015652     EISSN: 14230062     Source Type: Journal    
DOI: 10.1159/000346195     Document Type: Article

References (43)

1. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2010; 375: 181-183.
2. Argo CK, Caldwell SH: Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 511-513.
3. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH: Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371-379.
4. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117. (Pubitemid 30044177)
5. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395. (Pubitemid 39657013)
6. Rinella ME, Alonso E, Rao S, Whitington P, Fryer J, Abecassis M, Superina R, Flamm SL, Blei AT: Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl 2001; 7: 409-414. (Pubitemid 32492578)
7. Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, Nochajski TH, Trevisan M: Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology 2004; 39: 754-763. (Pubitemid 38337655)
8. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH: Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465.
9. Romeo S, Sentinelli F, Dash S, Yeo GS, Savage DB, Leonetti F, Capoccia D, Incani M, Maglio C, Iacovino M, O'Rahilly S, Baroni MG: Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes (Lond) 2010; 34: 190-194.
10. Speliotes EK, Butler JL, Palmer CD, Voight BF, GIANT Consortium, MIGen Consortium, NASH CRN, Hirschhorn JN: PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010; 52: 904-912.
11. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al: Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7:e1001324.
12. Wood GC, Chu X, Manney C, Strodel W, Petrick A, Gabrielsen J, Seiler J, Carey D, Argyropoulos G, Benotti P, Still CD, Gerhard GS: An electronic health record-enabled obesity database. BMC Med Inform Decis Mak 2012; 12: 45.
13. Gerhard GS, Chokshi R, Still CD, Benotti P, Wood GC, Freedman-Weiss M, Rider C, Petrick AT: The influence of iron status and genetic polymorphisms in the HFE gene on the risk for postoperative complications after bariatric surgery: a prospective cohort study in 1,064 patients. Patient Saf Surg 2011; 5: 1.
14. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474. (Pubitemid 29420675)
15. Still CD, Wood GC, Chu X, Erdman R, Manney CH, Benotti PN, Petrick AT, Strodel WE, Mirshahi UL, Mirshahi T, Carey DJ, Gerhard GS: High allelic burden of four obesity SNPs is associated with poorer weight loss outcomes following gastric bypass surgery. Obesity (Silver Spring). 2011; 19: 1676-1683.
16. Christou N, Efthimiou E: Five-year outcomes of laparoscopic adjustable gastric banding and laparoscopic roux-en-Y gastric bypass in a comprehensive bariatric surgery program in Canada. Can J Surg 2009; 52:E249-E258.
17. Jakobsen GS, Hofso D, Roislien J, Sandbu R, Hjelmesaeth J: Morbidly obese patients-who undergoes bariatric surgery? Obes Surg 2010; 20: 1142-1148.
18. LABS Writing Group for the LABS Consortium; Belle SH, Chapman W, Courcoulas AP, Flum DR, Gagner M, et al: Relationship of body mass index with demographic and clinical characteristics in the longitudinal assessment of bariatric surgery (LABS). Surg Obes Relat Dis 2008; 4: 474-480.
19. Chatrath H, Vuppalanchi R, Chalasani N: Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 2012; 32: 22-29.
20. Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ: A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009; 50: 2111-2116.
21. Sookoian S, Pirola CJ: Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-1894.
22. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, et al: Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209-1217.
23. Krarup NT, Grarup N, Banasik K, Friedrichsen M, Færch K, Sandholt CH, Jørgensen T, Poulsen P, Witte DR, Vaag A, Sørensen T, Pedersen O, Hansen T: The PNPLA3 rs738409 G-allele associates with reduced fasting serum triglyceride and serum cholesterol in Danes with impaired glucose regulation. PLoS One 2012; 7:e40376.
24. Palmer CN, Maglio C, Pirazzi C, Burza MA, Adiels M, Burch L, et al: Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS One 2012; 7:e39362.
25. Bi M, Kao WH, Boerwinkle E, Hoogeveen RC, Rasmussen-Torvik LJ, Astor BC, North KE, Coresh J, Köttgen A: Association of rs780094 in GCKR with metabolic traits and incident diabetes and cardiovascular disease: the ARIC study. PLoS One 2010; 5:e11690.
26. Onuma H, Tabara Y, Kawamoto R, Shimizu I, Kawamura R, Takata Y, Nishida W, Ohashi J, Miki T, Kohara K, Makino H, Osawa H: The GCKR rs780094 polymorphism is associated with susceptibility of type 2 diabetes, reduced fasting plasma glucose levels, increased triglycerides levels and lower HOMA-IR in Japanese population. J Hum Genet 2010; 55: 600-604.
27. Pollin TI, Jablonski KA, McAteer JB, Saxena R, Kathiresan S, Kahn SE, Goldberg RB, Altshuler D, Florez JC, Diabetes Prevention Program Research Group: Triglyceride response to an intensive lifestyle intervention is enhanced in carriers of the GCKR Pro446Leu polymorphism. J Clin Endocrinol Metab 2011; 96:E1142-E1147.
28. Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, et al: Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 2008; 40: 189-197. (Pubitemid 351171402)
29. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al: Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008; 40: 161-169. (Pubitemid 351171403)
30. Zhou L, Ding H, Zhang X, He M, Huang S, Xu Y, Shi Y, Cui G, Cheng L, Wang QK, Hu FB, Wang D, Wu T: Genetic variants at newly identified lipid loci are associated with coronary heart disease in a Chinese Han population. PLoS One 2011; 6:e27481.
31. Rauch U, Feng K, Zhou XH: Neurocan: a brain chondroitin sulfate proteoglycan. Cell Mol Life Sci 2001; 58: 1842-1856. (Pubitemid 33108773)
32. Retzler C, Gohring W, Rauch U: Analysis of neurocan structures interacting with the neural cell adhesion molecule N-CAM. J Biol Chem 1996; 271: 27304-27310. (Pubitemid 26367284)
33. Friedlander DR, Milev P, Karthikeyan L, Margolis RK, Margolis RU, Grumet M: The neuronal chondroitin sulfate proteoglycan neurocan binds to the neural cell adhesion molecules ng-CAM/L1/NILE and N-CAM, and inhibits neuronal adhesion and neurite outgrowth. J Cell Biol 1994; 125: 669-680. (Pubitemid 24149848)
34. Grumet M, Milev P, Sakurai T, Karthikeyan L, Bourdon M, Margolis RK, Margolis RU: Interactions with tenascin and differential effects on cell adhesion of neurocan and phosphacan, two major chondroitin sulfate proteoglycans of nervous tissue. J Biol Chem 1994; 269: 12142-12146. (Pubitemid 24196713)
35. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR: A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249.
36. Lam TK, Gutierrez-Juarez R, Pocai A, Bhanot S, Tso P, Schwartz GJ, Rossetti L: Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins. Nat Med 2007; 13: 171-180.
37. Nogueiras R, Wiedmer P, Perez-Tilve D, Veyrat-Durebex C, Keogh JM, Sutton GM, et al: The central melanocortin system directly controls peripheral lipid metabolism. J Clin Invest 2007; 117: 3475-3488. (Pubitemid 350097003)
38. van den Hoek AM, Voshol PJ, Karnekamp BN, Buijs RM, Romijn JA, Havekes LM, Pijl H: Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin. Diabetes 2004; 53: 2529-2534. (Pubitemid 39299258)
39. Powley TL: Vagal circuitry mediating cephalic-phase responses to food. Appetite 2000; 34: 184-188.
40. Bruinstroop E, Pei L, Ackermans MT, Foppen E, Borgers AJ, Kwakkel J, Alkemade A, Fliers E, Kalsbeek A: Hypothalamic neuropeptide Y (NPY) controls hepatic VLDL-triglyceride secretion in rats via the sympathetic nervous system. Diabetes 2012; 61: 1043-1050.
41. Robertson MD, Mason AO, Frayn KN: Timing of vagal stimulation affects postprandial lipid metabolism in humans. Am J Clin Nutr 2002; 76: 71-77. (Pubitemid 34686551)
42. Cohn JS, Wagner DA, Cohn SD, Millar JS, Schaefer EJ: Measurement of very low density and low density lipoprotein apolipoprotein (apo) B-100 and high density lipoprotein apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J Clin Invest 1990; 85: 804-811. (Pubitemid 20087484)
43. Stafford JM, Yu F, Printz R, Hasty AH, Swift LL, Niswender KD: Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion. Diabetes 2008; 57: 1482-1490.